[
  {
    "ts": null,
    "headline": "The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock.",
    "summary": "The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether  Eli Lilly  blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage.  Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine sold by  Novo Nordisk  —jumped as soon as the filing appeared on the court website, and ended the day up 11%.  The continued delay from the FDA creates even more uncertainty in the market for GLP-1 obesity drugs, which has been flooded with legal, low-price knockoffs of Lilly’s Zepbound and Novo’s Wegovy.",
    "url": "https://finnhub.io/api/news?id=f0b95001d0d4872155e3b75addc0b6d5a08686735579a310a92f7ebea7be141b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732226160,
      "headline": "The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock.",
      "id": 131554435,
      "image": "https://s.yimg.com/ny/api/res/1.2/83YXBXWL69fm4vuXxGNUYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/55bd65cbae3fdbc35986776ccc2881f5",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether  Eli Lilly  blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage.  Shares of the telemedicine company Hims & Hers—which markets a compounded version of a similar medicine sold by  Novo Nordisk  —jumped as soon as the filing appeared on the court website, and ended the day up 11%.  The continued delay from the FDA creates even more uncertainty in the market for GLP-1 obesity drugs, which has been flooded with legal, low-price knockoffs of Lilly’s Zepbound and Novo’s Wegovy.",
      "url": "https://finnhub.io/api/news?id=f0b95001d0d4872155e3b75addc0b6d5a08686735579a310a92f7ebea7be141b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=1aa3692dbae7e19eab3a2ca8abee96723d721e5b3dc6225c8cc1ad3903ffbccb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732206780,
      "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "id": 131598542,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=1aa3692dbae7e19eab3a2ca8abee96723d721e5b3dc6225c8cc1ad3903ffbccb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock: Unexpected Developments (Rating Downgrade)",
    "summary": "Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.",
    "url": "https://finnhub.io/api/news?id=8dba672ef37d68756bf83608066d12fd631a9f63c6a8402fd2f0641c0046b39f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732206364,
      "headline": "Eli Lilly Stock: Unexpected Developments (Rating Downgrade)",
      "id": 131547530,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284860965/image_1284860965.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.",
      "url": "https://finnhub.io/api/news?id=8dba672ef37d68756bf83608066d12fd631a9f63c6a8402fd2f0641c0046b39f"
    }
  },
  {
    "ts": null,
    "headline": "Is Now a Good Time to Buy the Dip in Eli Lilly Stock?",
    "summary": "Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.",
    "url": "https://finnhub.io/api/news?id=dbe5fa085d36fedc37e8495a91ca32427da2981e1b0c08381d19fcc1e06258c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732201200,
      "headline": "Is Now a Good Time to Buy the Dip in Eli Lilly Stock?",
      "id": 131540713,
      "image": "https://g.foolcdn.com/editorial/images/798070/getty-investing-time-to-sell.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.",
      "url": "https://finnhub.io/api/news?id=dbe5fa085d36fedc37e8495a91ca32427da2981e1b0c08381d19fcc1e06258c4"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Corefolio Allocation Fund Q3 2024 Commentary",
    "summary": "Franklin Corefolio Allocation Fund seeks capital appreciation through a diversified, multidisciplined approach. Read more here.",
    "url": "https://finnhub.io/api/news?id=fcc06068c3ec693b4884222ce6899038c753f92f8972f5db9e4b7b24d6ca0a52",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732189680,
      "headline": "Franklin Corefolio Allocation Fund Q3 2024 Commentary",
      "id": 131541199,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453953453/image_1453953453.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Franklin Corefolio Allocation Fund seeks capital appreciation through a diversified, multidisciplined approach. Read more here.",
      "url": "https://finnhub.io/api/news?id=fcc06068c3ec693b4884222ce6899038c753f92f8972f5db9e4b7b24d6ca0a52"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia Insiders Plan Big Stock Sales. CEO Jensen Huang Isn’t One of Them.",
    "summary": "Nvidia Insiders Plan Big Stock Sales. CEO Jensen Huang Isn’t One of Them.",
    "url": "https://finnhub.io/api/news?id=3c3fa902efea40252a9d4ffa053edc79af7e9ba57d0e364a3e554b2c3fa2bd66",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732189020,
      "headline": "Nvidia Insiders Plan Big Stock Sales. CEO Jensen Huang Isn’t One of Them.",
      "id": 131544414,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Nvidia Insiders Plan Big Stock Sales. CEO Jensen Huang Isn’t One of Them.",
      "url": "https://finnhub.io/api/news?id=3c3fa902efea40252a9d4ffa053edc79af7e9ba57d0e364a3e554b2c3fa2bd66"
    }
  },
  {
    "ts": null,
    "headline": "MoonLake Immunotherapeutics: A Somewhat Complicated Story",
    "summary": "MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for hidradenitis suppurativa (HS) is expected. Read the full report.",
    "url": "https://finnhub.io/api/news?id=d8804c45dc0a76ad93ca257c6d6973b3343e0a320c6d0316648e6632731f2179",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732184709,
      "headline": "MoonLake Immunotherapeutics: A Somewhat Complicated Story",
      "id": 131539801,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295493003/image_1295493003.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for hidradenitis suppurativa (HS) is expected. Read the full report.",
      "url": "https://finnhub.io/api/news?id=d8804c45dc0a76ad93ca257c6d6973b3343e0a320c6d0316648e6632731f2179"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Verge announce milestones in ALS collaboration",
    "summary": "Verge Genomics announced that Eli Lilly (LLY) has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis, or ALS, as part of the companies’ collaboration, which was initiated in July 2021. The targets were identified and validated by Verge’s AI-enabled Converge platform, with 83% of prioritized targets validated in disease-relevant models, a rate significantly higher than industry standards, demonstrating the robust predictive power o",
    "url": "https://finnhub.io/api/news?id=e9b6bfaa71245339f0bf7a20014598a5953d8c6ccdd1a88cef3f1b7146e47da2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732184131,
      "headline": "Eli Lilly, Verge announce milestones in ALS collaboration",
      "id": 131537401,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Verge Genomics announced that Eli Lilly (LLY) has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis, or ALS, as part of the companies’ collaboration, which was initiated in July 2021. The targets were identified and validated by Verge’s AI-enabled Converge platform, with 83% of prioritized targets validated in disease-relevant models, a rate significantly higher than industry standards, demonstrating the robust predictive power o",
      "url": "https://finnhub.io/api/news?id=e9b6bfaa71245339f0bf7a20014598a5953d8c6ccdd1a88cef3f1b7146e47da2"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Growth Opportunities Fund Q3 2024 Commentary",
    "summary": "The Franklin Growth Opportunities Fund outperformed the Russell 3000 Growth Index benchmark in the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=3fd9eda020f7e48cdf209bc622dac3b8e7ffdf732859b602ddec55fc242513c4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732182900,
      "headline": "Franklin Growth Opportunities Fund Q3 2024 Commentary",
      "id": 131539182,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1409892847/image_1409892847.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Franklin Growth Opportunities Fund outperformed the Russell 3000 Growth Index benchmark in the third quarter of 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=3fd9eda020f7e48cdf209bc622dac3b8e7ffdf732859b602ddec55fc242513c4"
    }
  },
  {
    "ts": null,
    "headline": "Versant startup sets out to make a new type of obesity drug",
    "summary": "The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.",
    "url": "https://finnhub.io/api/news?id=07850aa720da23f4bda0565cf6bfcc5c2500badd823aa2398d55f04210f2e82b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732181700,
      "headline": "Versant startup sets out to make a new type of obesity drug",
      "id": 131542210,
      "image": "https://imgproxy.divecdn.com/xCJEPS5NjIAsXymjiNftbljZrn8mJA4Obkp0j2GkDSw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9wZXAydGFuZ28ucG5n.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.",
      "url": "https://finnhub.io/api/news?id=07850aa720da23f4bda0565cf6bfcc5c2500badd823aa2398d55f04210f2e82b"
    }
  },
  {
    "ts": null,
    "headline": "HQH: Declines Bring Potential Opportunity",
    "summary": "Click here for analysis of HQH closed-end fund: regulatory uncertainty causing pressure, 12% managed distribution policy appeals to yield investors, heavy biotech focus.",
    "url": "https://finnhub.io/api/news?id=44c239cfeeb0fdc5a3deef0037108a1235f7ce99d7fadd3646dc4ce776b971e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732181066,
      "headline": "HQH: Declines Bring Potential Opportunity",
      "id": 131538682,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1255266014/image_1255266014.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Click here for analysis of HQH closed-end fund: regulatory uncertainty causing pressure, 12% managed distribution policy appeals to yield investors, heavy biotech focus.",
      "url": "https://finnhub.io/api/news?id=44c239cfeeb0fdc5a3deef0037108a1235f7ce99d7fadd3646dc4ce776b971e3"
    }
  },
  {
    "ts": null,
    "headline": "Franklin DynaTech Fund Q3 2024 Commentary",
    "summary": "Global equities ended the third quarter collectively higher as they recovered from bouts of volatility, some of which was stoked by US recession concerns.",
    "url": "https://finnhub.io/api/news?id=009cf55b66359acc974bdd26f19d0ddd5cdd631f705ed3c9796c9de20c842984",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732174800,
      "headline": "Franklin DynaTech Fund Q3 2024 Commentary",
      "id": 131536711,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/551986071/image_551986071.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Global equities ended the third quarter collectively higher as they recovered from bouts of volatility, some of which was stoked by US recession concerns.",
      "url": "https://finnhub.io/api/news?id=009cf55b66359acc974bdd26f19d0ddd5cdd631f705ed3c9796c9de20c842984"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop",
    "summary": "Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come.",
    "url": "https://finnhub.io/api/news?id=dfda1926e671678dccbbb12ba7b032825f7eee768857c878c107a51f6206f74c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732172400,
      "headline": "Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop",
      "id": 131527116,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come.",
      "url": "https://finnhub.io/api/news?id=dfda1926e671678dccbbb12ba7b032825f7eee768857c878c107a51f6206f74c"
    }
  },
  {
    "ts": null,
    "headline": "Hershey: A Deep Dive Into A Confectionery Giant Facing Headwinds",
    "summary": "Despite attractive valuation metrics, Hershey faces challenges like stagnant earnings growth. Read why HSY stock is a compelling value investment.",
    "url": "https://finnhub.io/api/news?id=cbc0a2fda0a87b25b086c083b50c5017d9e3a09025edf96090bb5d2e62d6b3af",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732148572,
      "headline": "Hershey: A Deep Dive Into A Confectionery Giant Facing Headwinds",
      "id": 131525033,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1410855811/image_1410855811.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Despite attractive valuation metrics, Hershey faces challenges like stagnant earnings growth. Read why HSY stock is a compelling value investment.",
      "url": "https://finnhub.io/api/news?id=cbc0a2fda0a87b25b086c083b50c5017d9e3a09025edf96090bb5d2e62d6b3af"
    }
  }
]